Thera-SAbDab

DARATUMUMAB

>   Structural Summary
TherapeuticDaratumumab
TargetCD38
Heavy ChainEVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKGLEWVSAISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKILWFGEPVFDYWGQGTLVTVSS
Light ChainEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)Active
Recorded Developmental TechnologyMedarex HuMAb Mouse
INN Year Proposed2009
INN Year Recommended2010
Companies InvolvedBoston Medical Center, Bristol-Myers Squibb, Dana-Farber Cancer Institute, French Innovative Leukemia Organisation, Genentech, Genmab, Janssen Biotech, Janssen Research & Development, M. D. Anderson Cancer Center, Syros Pharmaceuticals
Conditions ApprovedMultiple myeloma
Conditions ActiveAmyloid light-chain amyloidosis, Acute myeloid leukaemia, Chronic lymphocytic leukaemia, Diffuse large B cell lymphoma, Follicular lymphoma, Mantle-cell lymphoma, Myelodysplastic syndromes, Precursor B-cell lymphoblastic leukaemia-lymphoma, Precursor T-cell lymphoblastic leukaemia-lymphoma, Prostate cancer, T-cell lymphoma, Waldenstrom's macroglobulinaemia, Solid tumours
Conditions DiscontinuedNon-small cell lung cancer
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]